<?xml version="1.0" encoding="UTF-8"?>
<p>The most critical issues relate directly to the need for an appropriate frame for a decision-making procedure within the “real-life” clinical setting, when facing the choice between the innovator (original medicinal product) and its “similar” medicinal product. In fact, we are unable to implement for NBCDs the simple interchangeability decision which is normally the case after regulatory approval of generics (
 <xref rid="B6" ref-type="bibr">6</xref>) (
 <xref rid="T2" ref-type="table">Table 2</xref>).
</p>
